When a patient begins chemotherapy, the fight is double one against the cancer cells, and another against the side effects that can linger long after the last ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈